Please login to the form below

Not currently logged in
Email:
Password:

DCVax-L

This page shows the latest DCVax-L news and features for those working in and with pharma, biotech and healthcare.

BMS' Opdivo set for early access in UK

BMS' Opdivo set for early access in UK

Until now, the only PIM granted under the scheme was for Northwest Biotherapeutics' cell-based therapy DCVax-L for a form of brain cancer known as malignant glioma.

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics